<!DOCTYPE html>
<html>
<head>
<title>Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)</title>
<link href="/investors/stylesheets/ir.stockpr.css" rel="stylesheet" type="text/css">
<script type="text/javascript" src="https://ir.stockpr.com/javascripts/ir.js"></script>
<link rel="stylesheet" type="text/css" href="https://ir.stockpr.com/stylesheets/xbrl.css">
<script type="text/javascript" src="https://d1io3yog0oux5.cloudfront.net/_18bb9221bfaceea90b103087e143a388/aptose/files/theme/js/aside/ir/_js/all.js"></script>
</head>
<body>
<style>
body {
font-family: Arial, Helvetica, sans-serif;
font-size: 12px;
color: #454545;
}
</style>
<div class="xbrl-content">
    <h3>Quarterly report pursuant to Section 13 or 15(d)</h3>
    <div id="xbrl-menu-top">
        <div class="navigation">
            <ul class="xbrl-sf-menu">
                
                    <li>
                        <a class="menu-item " href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/840">Cover</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/840">Document And Entity Information</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item current" href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/841">Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/841">Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/842">Condensed Consolidated Interim Statements of Financial Position (Current Period Unaudited) (Parentheticals)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/843">Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/844">Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/845">Condensed Consolidated Interim Statements of Cash Flows (Unaudited)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/846">Notes to Financial Statements</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/846">Note 1 - Reporting Entity</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/847">Note 2 - Significant Accounting Policies</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/848">Note 3 - Cash and Cash Equivalents</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/849">Note 4 - Prepaid Expenses</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/850">Note 5 - Right-of-use Assets</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/851">Note 6 - Investments</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/852">Note 7 - Fair Value Measurements and Financial Instruments</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/853">Note 8 - Accrued Liabilities</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/854">Note 9 - Lease Liability</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/855">Note 10 - Share Capital</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/856">Note 11 - Stock-based Compensation</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/857">Note 12 - Subsequent Events</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/858">Accounting Policies</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/858">Significant Accounting Policies (Policies)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/859">Notes Tables</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/859">Note 4 - Prepaid Expenses (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/860">Note 5 - Right-of-use Assets (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/861">Note 6 - Investments (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/862">Note 7 - Fair Value Measurements and Financial Instruments (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/863">Note 8 - Accrued Liabilities (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/864">Note 9 - Lease Liability (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/865">Note 10 - Share Capital (Tables)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/866">Note 11 - Stock-based Compensation (Tables)</a></li>
                                                    </ul>
                    </li>
                                    <li>
                        <a class="menu-item " href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/867">Notes Details</a>
                        <ul class="submenu">
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/867">Note 3 - Cash and Cash Equivalents (Details Textual)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/868">Note 4 - Prepaid Expenses - Prepaid Expenses and Other Assets (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/869">Note 5 - Right-of-use Assets - Schedule of Right-of-use Assets (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/870">Note 6 - Investments - Investments (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/871">Note 7 - Fair Value Measurements and Financial Instruments - Assets Measured on a Recurring Basis (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/872">Note 8 - Accrued Liabilities - Accrued Expenses (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/873">Note 9 - Lease Liability (Details Textual)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/874">Note 9 - Lease Liability - Schedule of Minimum Payments Under Operating Leases (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/875">Note 9 - Lease Liability - Lease Liability (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/876">Note 9 - Lease Liability - Operating Lease Cost (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/877">Note 10 - Share Capital (Details Textual)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/878">Note 10 - Share Capital - Loss Per Share (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/879">Note 11 - Stock-based Compensation (Details Textual)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/880">Note 11 - Stock-based Compensation - Stock Option Transactions (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/881">Note 11 - Stock-based Compensation - Weighted Average Assumptions (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/882">Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/883">Note 11 - Stock-based Compensation - Vesting Terms of Options Granted (Details) (Parentheticals)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/884">Note 11 - Stock-based Compensation - Restricted Stock Units (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/885">Note 11 - Stock-based Compensation - Share-based Payment Expense (Details)</a></li>
                                                            <li><a href="/investors/sec-filings/all-sec-filings/xbrl_doc_only/886">Note 12 - Subsequent Events (Details Textual)</a></li>
                                                    </ul>
                    </li>
                            </ul>
        </div>
    </div>
    <div class="spr-xbrl-document">
        <h4>Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)</h4>
                <div style="clear:both;"></div>
    </div>
</div>
</body>
</html>